Aclaris Cash Ratio from 2010 to 2024

ACRS Stock  USD 4.07  0.25  6.54%   
Aclaris Therapeutics Cash Ratio yearly trend continues to be comparatively stable with very little volatility. Cash Ratio will likely drop to 1.22 in 2024. From the period from 2010 to 2024, Aclaris Therapeutics Cash Ratio quarterly data regression had r-value of (0.85) and coefficient of variation of  104.92. View All Fundamentals
 
Cash Ratio  
First Reported
2010-12-31
Previous Quarter
1.28838201
Current Value
1.22
Quarterly Volatility
10.67041044
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 819.9 K, Interest Expense of 3.2 M or Selling General Administrative of 21.3 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0 or PTB Ratio of 0.67. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aclaris Therapeutics Correlation against competitors.
For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.

Latest Aclaris Therapeutics' Cash Ratio Growth Pattern

Below is the plot of the Cash Ratio of Aclaris Therapeutics over the last few years. It is Aclaris Therapeutics' Cash Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aclaris Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash Ratio10 Years Trend
Slightly volatile
   Cash Ratio   
       Timeline  

Aclaris Cash Ratio Regression Statistics

Arithmetic Mean10.17
Geometric Mean5.34
Coefficient Of Variation104.92
Mean Deviation9.34
Median4.85
Standard Deviation10.67
Sample Variance113.86
Range24.9327
R-Value(0.85)
Mean Square Error34.31
R-Squared0.72
Significance0.000063
Slope(2.02)
Total Sum of Squares1,594

Aclaris Cash Ratio History

2024 1.22
2023 1.29
2022 2.06
2021 1.19
2020 3.64
2019 1.6
2018 2.09

About Aclaris Therapeutics Financial Statements

Aclaris Therapeutics shareholders use historical fundamental indicators, such as Cash Ratio, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aclaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aclaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Ratio 1.29  1.22 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.